The following slide from NEU's recent slide pack is worth studying as it explains whare areas its drug target.
NEU's don't cure the syndrome but they Trofinetide / Daybue and NNZ-2591 improve they address "impaired communication between neurons, abnormal formation/pruning of dendrites & chronic inflammation" if taken twice daily.
For the 2591 PMS Phase 2 clinical trial, the following slide (from 8 Nov 2023) contains preclinical testing data and is well worth studying.
Read the small print under each of the bar charts.
Similar preclinical results were obtained for the other three (Pitt Hopkins, Angelman and Prader-Willi
syndrome) 2591 Phase 2 trials currently in progress. See latest slide pack
Phelan-McDermid Syndrome (PMS)
GLTA
Moonsoon Briefing Thurs 20 April, page-87
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.13 |
Change
0.780(5.44%) |
Mkt cap ! $1.927B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.13 | $14.35 | $4.002M | 269.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 375 | $15.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.14 | 1594 | 18 |
View Market Depth
| Last trade - 14.08pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |